Cytochrome P450 inhibiting/inducing medication use among patients with advanced ovarian cancer who receive or are eligible for poly (ADP-ribose) polymerase inhibitors as first line maintenance therapy

Poly (ADP-ribose) polymerase inhibitors (PARPi) share similar mechanisms of action but differ in their metabolism. Niraparib is metabolized in the liver by carboxylesterase-catalyzed amide hydrolysis, while other PARPis are metabolized by the cytochrome P450 (CYP) system. Patients (pts) with advanced epithelial ovarian cancer (aOC) on concomitant medications also metabolized by the CYP system may have potential drug-drug interactions (DDIs) that may reduce PARPi efficacy and tolerability. Due to its unique pharmacokinetics, niraparib may be a more suitable option for these pts. This US-based real-world study aimed to quantify the proportion of pts. with aOC using CYP inhibiting/inducing (i/i) medications during PARPi initiation or eligibility in the first-line maintenance (1Lm) setting and describe their demographic/clinical characteristics.